New research paves way for anti-cancer treatment

Monday, October 31, 2016

London: Researchers at the University of Huddersfield have developed a new lab technique that may aid the development and success rate of an important anti-cancer treatment. Used particularly in cases of liver cancer, polymer beads are injected into arteries that feed a tumour, where they block the blood flow, cutting off the supply of oxygen and nutrients. The beads then also release an anticancer drug directly into the tumour, reducing the systemic side effects.

Tania Swaine and Laura Waters, University of Huddersfield

Tania Swaine and Laura Waters, University of Huddersfield

What developers need is a safe way of predicting what would happen in a patient’s body if the beads and the drug they contain are modified. Now the new research has provided them with a method and the findings are described in an article in the European Journal of Pharmaceutical Sciences.

“There was no lab mimic that was able to adequately predict how the drug was released from these drug-eluting beads once they were in the body,” said one of the co-authors, University of Huddersfield pharmaceutical science lecturer and researcher Dr Laura Waters. “The article describes a way of doing it in the lab. We compared our results with in vivo data and proved that the method worked.”

Dr Waters is supervising the PhD researcher Tanya Swaine, a graduate of the University of Huddersfield whose doctoral project is sponsored by the company BTG, which manufactures the embolization beads that are used in the therapy.

Tanya and co-researchers were able to carry out lab experiments in which a buffer – a liquid that mimics blood – was pumped at different rates through the beads. They also modified the quantities of drug contained in the beads. By comparing their laboratory observations with in vivo data, the research team was able to establish the validity of their simulation technique.

It will be of practical value to any medical researcher working on a bead-based system, said Dr Waters, enabling them to make accurate predictions without running any risks to patients.

Professor Andy Lewis, Director of R&D at BTG and industrial supervisor in the collaboration commented: “We are continually innovating our drug-eluting bead technologies to introduce new features, such as X-ray visibility or biodegradability. It’s important from a product development perspective that if we wanted to put other drugs into the beads, or change anything about their chemistry, we could use this system to predict product behaviour before it is given to people.”

Categories: Oncology, RESEARCH

Tags: , , , , , , ,

  More from Oncology

As radiation therapy declined so did second cancers in childhood cancer survivors


Vaccine shows promising results for early-stage breast cancer patients


More complications, less satisfaction in breast cancer patients who get radiation, implants


Safety concerns linger for generic oncology drugs in developing countries


New research paves way for anti-cancer treatment


Precision medicine test helps guide breast cancer patients’ chemotherapy decision

Comments »

No comments yet.

Name (required)
E-mail (required - never shown publicly)
URI
Your Comment (smaller size | larger size)
You may use <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong> in your comment.